版本:
中国

BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab

Oct 10Innate Pharma SA :

* Announced on Sunday safety data for two Phase I studies conducted by Bristol-Myers Squibb

* Combination of lirilumab and nivolumab in Phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy

* Data supports ongoing Phase I cohort expansion of lirilumab in combination with nivolumab

* Efficacy data will be presented at Society for Immunotherapy of Cancer 2016 conference

Source text for Eikon:

Further company coverage:

(Gdynia Newsroom)

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐